Candel Therapeutics: Entering Its Pivotal Year
Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. Find out why I rate CADL stock ...
Europe Approves Merck's Cancer Drug For Two Indications
On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral ...
Le Lézard5 天
Genprex Provides Update on Diabetes Gene Therapy Program
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the advancement ...
Merck receives European Commission approval for WELIREG in two indications
Merck (MRK) announced that the European Commission has conditionally approved WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, ...
Rezolute: Late-Stage Study Targeting Hyperinsulinism
Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.